Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | PLEC | Q15149 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6782253 | 0.91 | MAPT (0.51) | SMN1; SMN2MEN1KMT2AGAABRD4 | |
| SCHEMBL506325 | 0.90 | PRKCI (0.46) | SMN1; SMN2PRKCIMEN1KMT2AGAA | |
| SCHEMBL29276650 | 0.89 | KMT2A (0.41) | SMN1; SMN2PRKCIKMT2AGAABRD4 | |
| SCHEMBL29276987 | 0.86 | PRKCI (0.40) | SMN1; SMN2PRKCIMEN1KMT2AGAA | |
| SCHEMBL1269634 | 0.85 | NQO2 (0.54) | SMN1; SMN2PRKCIMEN1KMT2AGAA | |
| SCHEMBL30407813 | 0.85 | NQO2 (0.54) | SMN1; SMN2PRKCIMEN1KMT2AGAA | |
| SCHEMBL6779574 | 0.84 | ALDH1A1 (0.52) | SMN1; SMN2MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL28798220 | 0.82 | ADRA2C (0.47) | SMN1; SMN2PRKCIMEN1KMT2AGAA | |
| SCHEMBL6775774 | 0.81 | PRKCI (0.46) | PRKCIGAAALDH1A1MAPTPTGER4 | |
| SCHEMBL6779269 | 0.81 | ADRA2C (0.41) | SMN1; SMN2PRKCIMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300154-B2 | Anticoagulant derivatives for cardiovascular imaging | ELMALEH DAVID R (US) | 2019-05-28 | — | — | US | disclosed |
| US-20170290931-A1 | ANTICOAGULANT DERIVATIVES FOR CARDIOVASCULAR IMAGING | ELMALEH DAVID R (US) | 2017-10-12 | — | — | US | disclosed |
| US-20170290931-A1 | ANTICOAGULANT DERIVATIVES FOR CARDIOVASCULAR IMAGING | ELMALEH DAVID R (US) | 2017-10-12 | — | — | US | disclosed |
| WO-2016044645-A1 | ANTICOAGULANT DERIVATIVES FOR CARDIOVASCULAR IMAGING | ELMALEH DAVID R (US) | 2016-03-24 | — | — | WO | disclosed |
| US-6710055-B2 | INDOLE AND BENZIMIDAZOLE ANTITHROMBOTIC COMPOUNDS, SUCH AS 1-METHYL-2-(N-AMIDINOPHENYL)-AMINOMETHYL)-5-(N-(HYDROXYCARBO QUINOLINE-8-SULFONYLAMINO)-INDOLE | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2004-03-23 | — | — | US | disclosed |
| US-20030004181-A1 | Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-02 | — | — | US | disclosed |
| US-6469039-B1 | BENZIMIDAZOLES; THROMBIN- INHIBITING ACTIVITY AND THE EFFECT OF EXTENDING THROMBIN TIME | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-22 | — | — | US | disclosed |
| US-6414008-B1 | CYNAO- OR AMIDINE-SUBSTITUTED BENZIMIDAZOLES, BENOTHIAZOLES, OR BENZOXAZOLES; 2-(N-(4-AMIDINOPHENYL)AMINOMETHYL)BENZOTHIAZOLES; 2-((4-CYANOPHENYL)OXYMETHYL)IMIDAZOL(4,5-B)PYRIDINES; ANTITHROMBOTICS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-07-02 | — | — | US | disclosed |
| US-6087380-A | ANTITHROMBOTIC BENZIMIDAZOLES; ANTICOAGULANTS; 2-(N-(4-AMIDINOPHENYL)-AMINOMETHYL)-BENZIMIDAZOL-5-YL-CARBOXYLIC ACIDS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300154-B2 | Anticoagulant derivatives for cardiovascular imaging | F3, TFPI, SERPINC1 | SMN1; SMN2 4774/4885PRKCI 2284/4885MEN1 760/4885 |
| US-20030004181-A1 | Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions | F2, TFPI, FGB | SMN1; SMN2 4229/4885PRKCI 2854/4885MEN1 1446/4885 |
| US-20170290931-A1 | ANTICOAGULANT DERIVATIVES FOR CARDIOVASCULAR IMAGING | F3, TFPI, SERPINC1 | SMN1; SMN2 4774/4885PRKCI 2284/4885MEN1 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.